Experiences with
Ibrutinib2,003 public posts
Want to take advantage of all our features? Just log in!
or
Leukemia-associated macrophages, their role in the CLL Tumor Micro-environment and how they affect progression and therapy response
Ibrutinib and BTK inhibition[/i]
[i] 3.2. Venetoclax[/i]
[i] 3.3. Anti-CD20 monoclonal antibodies and the phagocytic role of leukemia-associated macrophages[/i]
[i]4.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
[/i]
[i]In this cohort of the FLAIR trial in which patients with previously untreated CLL were randomly assigned to receive ibrutinib–venetoclax, ibrutinib monotherapy, or FCR, we found that MRD-guided ibrutinib–venetoclax was superior to FCR with respect to progression-free survival (97.2% vs. 76.8%